Trials / Completed
CompletedNCT01791244
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmart™ device.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rebif® |
Timeline
- Start date
- 2013-02-28
- Primary completion
- 2016-02-29
- Completion
- 2016-02-29
- First posted
- 2013-02-13
- Last updated
- 2017-08-24
- Results posted
- 2017-07-12
Locations
14 sites across 2 countries: Germany, Sweden
Source: ClinicalTrials.gov record NCT01791244. Inclusion in this directory is not an endorsement.